Haemonetics (HAE) Stock Breaks Higher With November Test Looming

TLDR

Table of Contents

Haemonetics stock surged nearly 16% after CSL Plasma announced plans to expand equipment use across U.S. centers.
CSL expects to complete the rollout across more than 300 U.S. plasma collection centers by December 2027.
BTIG raised its Haemonetics price target to $130, following Citi’s earlier upgrade to Buy.
Haemonetics reported $339.38 million in quarterly revenue and $0.72 in diluted earnings per share.
Investors await November 5 earnings for further details on the CSL agreement and expected revenue growth.

Haemonetics (HAE) stock rose 15.96% on Thursday, October 8, 2026, after CSL Plasma detailed a wider rollout of its plasma collection systems. Shares approached $118 during morning trading, compared with Wednesday’s $101.71 close. The announcement renewed attention on the medical equipment maker’s U.S. plasma business.

Haemonetics Corporation, HAE

CSL Plasma Sets Nationwide Rollout

CSL told Haemonetics it plans to introduce NexSys PCS devices with Persona PLUS technology at all its existing U.S. plasma centers. The company expects to finish the switch by December 2027. Its network includes more than 300 centers.

The update followed an August supply agreement that allowed CSL to buy Haemonetics equipment without minimum purchase requirements. The contract remains non-exclusive, and both companies must finalize rollout details. Earlier this week, European healthcare stocks gained, driven partly by clinical trial news.

Analysts Raise Haemonetics Stock Targets

BTIG raised its Haemonetics price target from $110 to $130 on Thursday while keeping a Buy rating. In September, Citi upgraded the stock from Neutral to Buy and increased its target from $92 to $123. The two decisions came weeks apart.

Citi estimated that each 10% recovery in CSL business could add $0.13 to annual earnings per share. Other analysts previously projected $183 million to $223 million in yearly sales if CSL completes a broad transition. Those figures remain estimates, not company guidance.

Quarterly Results and Vivasure Deal

Haemonetics reported $339.38 million in revenue for its June quarter, alongside diluted earnings of $0.72 per share. Revenue grew 5.6% from last year. Free cash flow reached roughly $39.1 million. Separately, U.S. stock indexes set records this week, although rising bond yields weighed on some healthcare shares.

Haemonetics also made progress with Vivasure Medical. A $6.1 million payment went to Orchestra BioMed after a milestone, bringing related consideration to $11 million. Future payments could reach another $10 million, depending on Vivasure revenue targets.

Valuation and November Earnings Update

Haemonetics carried around $1.17 billion in long-term debt and traded near 50 times earnings during Thursday’s rally. Its latest surge adds attention to that valuation. A recent retail investor survey also showed unusually high stock allocations across the broader market.

The company has not changed its fiscal 2027 forecast because rollout timing remains uncertain. Haemonetics plans to publish second-quarter results on November 5 and explain the expected CSL sales contribution.

✨ Limited Time Offer